Spectranetics starts Turbo elite post-marketing trial
This article was originally published in Clinica
Executive Summary
Colorado-based Spectranetics has begun a German trial of its Turbo elite laser catheters in combination with Turbo-Booster. The PATENT trial is a prospective registry of 100 patients to assess arterial patency as measured by duplex ultrasound at intervals up to 12 months after the procedure. It will also assess the device's safety. The Colorado Springs firm's Turbo elite line of laser catheters was approved by the FDA for the treatment of all stenoses and occlusions in the leg arteries in July.
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.